Parathyroid Hormone (Human, 1-34)
| Catalog number: | MDP0430 |
| CAS Number: | 90880-35-6 |
| Sequence: | Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe |
| Amount: | 500 ug |
| Molecular Weight: | 4117.6 g/mol |
| Supplied as: | Powder |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20 C |
| WARNING: | For in vitro Research Use Only. NOT for use on humans or animals. |
| Grade: | Biotechnology grade. All products are highly pure. |
References
- Luo Y, Li SY, Tian FM, Song HP, Zhang YZ, Zhang L. Effects of human parathyroid hormone 1-34 on bone loss and lumbar intervertebral disc degeneration in ovariectomized rats Int Orthop. 2018 May;42(5):1183-1190.
- Hu Z, Niu H, Yang X, Li H, Sang G, Li B. Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats Int J Pharm. 2006 Jul 24;317(2):144-54.
- Li H, Zhou Q, Bai BL, Weng SJ, Wu ZY, Xie ZJ, Feng ZH, Cheng L, Boodhun V, Yang L. Effects of combined human parathyroid hormone (1-34) and menaquinone-4 treatment on the interface of hydroxyapatite-coated titanium implants in the femur of osteoporotic rats J Bone Miner Metab. 2018 Nov;36(6):691-699.
- Ruan S, Yang G, Dong Y, Shangguan W, Lu W. Discovery of a Long-Acting Parathyroid Hormone 1-34 Analogue to Treat Hypoparathyroidism Mol Pharm. 2021 Sep 6;18(9):3260-3271.
- Tao ZS, Zhou WS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T, Lv YX, Cui W, Yang L. Intermittent administration of human parathyroid hormone (1-34) increases fixation of strontium-doped hydroxyapatite coating titanium implants via electrochemical deposition in ovariectomized rat femur J Biomater Appl. 2016 Feb;30(7):952-60.
- Goujard C, Salenave S, Briot K, Chanson P, Grimon G, Kamenick P. Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns Lancet. 2020 Apr 18;395(10232):1304.
- Tao ZS, Zhou WS, Tu KK, Huang ZL, Zhou Q, Sun T, Lv YX, Cui W, Yang L. The effects of combined human parathyroid hormone (1-34) and simvastatin treatment on osseous integration of hydroxyapatite-coated titanium implants in the femur of ovariectomized rats Injury. 2015 Nov;46(11):2164-9.
- Gafni RI, Langman CB, Guthrie LC, Brillante BA, James R, Yovetich NA, Boyce AM, Collins MT. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity J Bone Miner Res. 2018 Oct;33(10):1741-1747.
- Sturmer A, Mehta N, Giacchi J, Cagatay T, Tavakkol R, Mitta S, Fitzpatrick L, Wald J, Trang J, Stern W. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH] in postmenopausal women with osteoporosis Clin Pharmacokinet. 2013 Nov;52(11):995-1004.
